Phenylbutazone
- CAS No.
- 50-33-9
- Chemical Name:
- Phenylbutazone
- Synonyms
- PBZ;Benzone;4-Phenylbutazone;Bute;Butone;Azolid;Butalan;Butadione;Baotaisong;Butazolidin
- CBNumber:
- CB0370134
- Molecular Formula:
- C19H20N2O2
- Molecular Weight:
- 308.37
- MOL File:
- 50-33-9.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/12 17:58:41
| Melting point | 106-108 °C (lit.) |
|---|---|
| Boiling point | 448.76°C (rough estimate) |
| Density | 1.1591 (rough estimate) |
| refractive index | 1.6140 (estimate) |
| storage temp. | 2-8°C |
| solubility | Practically insoluble in water, sparingly soluble in alcohol. It dissolves in alkaline solutions. |
| form | Powder |
| pka | 4.5(at 25℃) |
| color | White to almost white |
| Water Solubility | <0.1 g/100 mL at 23.5 ºC |
| Merck | 14,7277 |
| BRN | 290080 |
| Stability | Stable. Incompatible with strong oxidizing agents, strong acids, strong bases. |
| InChIKey | VYMDGNCVAMGZFE-UHFFFAOYSA-N |
| LogP | 3.160 |
| CAS DataBase Reference | 50-33-9(CAS DataBase Reference) |
| NIST Chemistry Reference | Phenylbutazone(50-33-9) |
| IARC | 3 (Vol. 13, Sup 7) 1987 |
| EPA Substance Registry System | Phenylbutazone (50-33-9) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301-H312+H332-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P280-P301+P310-P302+P352+P312-P304+P340+P312-P305+P351+P338 | |||||||||
| Hazard Codes | Xn,T,F | |||||||||
| Risk Statements | 36/37/38-20/21/22-42/43-45-36-11 | |||||||||
| Safety Statements | 36/37/39-26-45-22-53-36/37-16 | |||||||||
| RIDADR | 3249 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | UQ8225000 | |||||||||
| TSCA | Yes | |||||||||
| HazardClass | 6.1(b) | |||||||||
| PackingGroup | III | |||||||||
| HS Code | 29331990 | |||||||||
| Toxicity | LD50 oral in rabbit: 781mg/kg | |||||||||
| NFPA 704 |
|
Phenylbutazone price More Price(10)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | P8386 | Phenylbutazone | 50-33-9 | 25G | ₹9677.55 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | P8386 | Phenylbutazone | 50-33-9 | 100G | ₹13271.45 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR2607 | Phenylbutazone pharmaceutical secondary standard, certified reference material | 50-33-9 | 500MG | ₹14700.35 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | P8386 | Phenylbutazone | 50-33-9 | 500G | ₹38645.25 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 80184 | Phenylbutazone certified reference material, TraceCERT? | 50-33-9 | 100MG | ₹8854.85 | 2022-06-14 | Buy |
Phenylbutazone Chemical Properties,Uses,Production
Description
Phenylbutazone, one of the earliest NSAIDs introduced, is now indicated for the symptomatic relief of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, gout, and acute superficial thrombophlebitis. The gastrointestinal and bone marrow toxicity observed in its early use have been greatly reduced by lower dosage (300 mg/d). Nevertheless, it is used primarily where other drugs have failed and then only for short-term therapy. The drug has a long serum half-life of about 100 h. It is a moderately active cyclooxygenase inhibitor and it suppresses both spontaneous and chemotactic motility of neutrophils. In addition to the serious gastrointestinal and hematological adverse effects, sodium and water retention, rash, vertigo, and dermatitis are observed.
Chemical Properties
Off-Whtie Solid
Uses
Phenylbutazone, a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of COX. Phenylbutazone-dependent inactivation of COX and prostacyclin synthase is markedly increased in the presence of 100 μM hydrogen peroxide with half-maximal effects at Phenylbutazone concentrations of 100 and 25 μM for COX and prostacyclin synthase, respectively.
World Health Organization (WHO)
Phenylbutazone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1949 for the treatment of rheumatic disorders. Its use was subsequently associated with serious and sometimes fatal adverse reactions, notably cases of aplastic anaemia and agranulocytosis. Many national drug regulatory authorities consider that more recently introduced drugs offer a safer alternative for most, if not all, patients requiring anti-inflammatory agents. Phenylbutazone has thus been either withdrawn at the national level or retained with rigorously restricted indications for patients unresponsive to other therapy. These restrictions also apply, in general, to combination products containing phenylbutazone.
General Description
Odorless white or off-white crystalline powder. Tasteless at first, but slightly bitter aftertaste. pH (aqueous solution) 8.2.
Air & Water Reactions
Phenylbutazone is relatively stable at ambient temperatures. Aqueous decomposition of Phenylbutazone occurs by hydrolysis and oxidation. Insoluble in water.
Reactivity Profile
Phenylbutazone is incompatible with strong oxidizers, strong acids and strong bases. .
Fire Hazard
Flash point data for Phenylbutazone are not available; however, Phenylbutazone is probably combustible.
Safety Profile
Suspected human carcinogen producing leukemia. A human poison by parenteral route. An experimental poison by ingestion, intraperitoneal, subcutaneous, intravenous, and intramuscular routes. Human systemic effects by ingestion and possibly other routes: fever, blood pressure increase, other unspecified vascular effects, damage to kidney tubules and glomeruli, decreased urine volume, blood in the urine, reduction in the number of whte blood cells, and agranulocytosis. Experimental teratogenic and reproductive effects. Human mutation data reported. An eye irritant. An antiinflammatory agent. When heated to decomposition it emits toxic fumes of NOx
Purification Methods
Crystallise the dione from EtOH. Its pK2 3 is 4.52 (in H2O), 4.89 (in 50% aqueous EtOH) and 5.25 (80% 2-methoxyethanol). It complexes with Hg2+, Cd2+ and Zn2+. It has UV with max at 239.5nm in MeOH+50% aqueous HClO4 and 264nm in aqueous 0.1N NaOH. [Beilstein 24 III/IV 1123.]
Phenylbutazone Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Afton Pharma | +91-9712000202 +91-9712000202 | Gujarat, India | 63 | 58 | Inquiry |
| Varahi International | +91-7922844991 +91-7922844991 | Gujarat, India | 24 | 58 | Inquiry |
| Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
| Reine Lifescience | +91-9820193549 +91-9825138460 | Gujarat, India | 19 | 58 | Inquiry |
| Heer Pharma Pvt Ltd | +91-9820051881 +91-9820051881 | Maharashtra, India | 102 | 58 | Inquiry |
| Century Pharmaceuticals Ltd | +91-2652361581 +91-2652361581 | Gujarat, India | 53 | 58 | Inquiry |
| Afton Pharma | 91-9712000202 | Gujarat, India | 40 | 58 | Inquiry |
| OCEAN TRADING CORPORATION | +91(22) 24921669 | New Delhi, India | 6211 | 58 | Inquiry |
| CHEMSWORTH | +91-261-2397244 | New Delhi, India | 6707 | 30 | Inquiry |
| Central Drug House(P) Ltd. | 91-11-49404040 | New Delhi, India | 6160 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| Afton Pharma | 58 |
| Varahi International | 58 |
| Ralington Pharma | 58 |
| Reine Lifescience | 58 |
| Heer Pharma Pvt Ltd | 58 |
| Century Pharmaceuticals Ltd | 58 |
| Afton Pharma | 58 |
| OCEAN TRADING CORPORATION | 58 |
| CHEMSWORTH | 30 |
| Central Drug House(P) Ltd. | 58 |
50-33-9(Phenylbutazone)Related Search:
1of4
chevron_right